MindWalk Holdings (HYFT) Income towards Parent Company (2020 - 2026)
MindWalk Holdings (HYFT) posted quarterly Income towards Parent Company of $930.12 for Q2 2026, down 99.9% year-over-year from $895979.1 in Q2 2025, and up 29.8% quarter-over-quarter from $716.55 in Q4 2025.
MindWalk Holdings (HYFT) Income towards Parent Company (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has reported Income towards Parent Company for 7 consecutive years, with $930.12 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income towards Parent Company fell 99.9% year-over-year to $930.12; the TTM figure through Apr 2026 stood at $821.7 million (up 421.75% YoY), while the FY2026 annual figure was $841120.4, down 59.78% from the prior year.
- Income towards Parent Company grew to $930.12 in Q2 2026 per HYFT's latest filing, from $716.55 in the prior quarter.
- Across five years, Income towards Parent Company topped out at $3.1 billion in Q3 2023 and bottomed at -$32.9 million in Q2 2023.
- Historically, Income towards Parent Company has averaged $313.9 million across 5 years, with a median of $727895.0 in 2024.
- Annual changes were most pronounced in 2022 — Income towards Parent Company plunged 328.73% — and 2023, when it jumped 1025793.57%.
- MindWalk Holdings' Income towards Parent Company stood at $3.9 million in 2022, then jumped by 32982.56% to $1.3 billion in 2023, then slumped by 99.94% to $727895.0 in 2024, then tumbled by 99.9% to $716.55 in 2025, then climbed by 29.8% to $930.12 in 2026.
- Business Quant data shows HYFT's Income towards Parent Company at $930.12 in Q2 2026, $716.55 in Q4 2025, and $821.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 930.12 |
| Oct 31, 2025 | 716.55 |
| Jul 31, 2025 | 821.67 Mn |
| Apr 30, 2025 | 895,979.08 |
| Jan 31, 2025 | 303,607.97 |
| Oct 31, 2024 | 727,894.97 |
| Jul 31, 2024 | 155.56 Mn |
| Apr 30, 2024 | -27.69 Mn |
| Jan 31, 2024 | 1.70 Mn |
| Oct 31, 2023 | 1.30 Bn |
| Jul 31, 2023 | 3.12 Bn |
| Apr 30, 2023 | -32.91 Mn |
| Jan 31, 2023 | 782,171.11 |
| Oct 31, 2022 | 3.93 Mn |
| Jul 31, 2022 | 304,605.58 |
| Apr 30, 2022 | -15.40 Mn |
| Jan 31, 2022 | -167,410.40 |
| Oct 31, 2021 | -4,326.39 |
| Jul 31, 2021 | -2,568.93 |
| Apr 30, 2021 | -3.59 Mn |